Press releaseGlobe Newswire
Propanc Biopharma
PPCB · NASDAQ
$0.321+$0.004 (+1.26%)TodayMarket closed ·
Prev close $0.317
Latest news
- Press releaseGlobe Newswire
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Crude Oil Moves Higher; Dollar General Shares Gain After Upbeat Q2 Earnings
- NewsVandana Singh
Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Results
- NewsAvi Kapoor
Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
- Press releaseGlobe Newswire
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings
- NewsAvi Kapoor
Dow Jumps Over 250 Points; US Initial Jobless Claims Rise
- Press releaseGlobe Newswire
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
- Press releaseBusiness Wire
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
Propanc Biopharma Files Provisional Patent For Fully Synthetic Recombinant PRP To Advance Long-Term Treatment Of Metastatic Cancer
- Press releaseGlobe Newswire
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
- Press releaseGlobe Newswire
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releaseGlobe Newswire
Propanc Biopharma Provides Shareholder Update
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- NewsAvi Kapoor
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsAvi Kapoor
US Stocks Mixed; Riskified Shares Dip After Q2 Results
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- Press releaseBusiness Wire
Propanc Biopharma's Peer Reviewed Articles for Proenzymes Cancer Treatment Generates "Unprecedented" Interest
- Press releaseBusiness Wire
Propanc Biopharma Receives Notice of Allowance for "Proenzyme Composition" Patent in North America
- Press releaseBusiness Wire
Propanc Biopharma's CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.